参芪扶正注射液调节多药耐药相关蛋白7改善紫杉醇和吉西他滨非小细胞肺癌耐药

Effect of Shenqi Fuzheng Injections on regulating the multidrug resistance-associated protein 7 and improving the resistance of paclitaxel and gemcitabine in non-small cell lung cancer

目的探讨参芪扶正注射液改善肺癌细胞紫杉醇和吉西他滨耐药的作用及机制。方法建立不同耐药细胞株,检测细胞存活率、胞内药物含量及多药耐药相关蛋白7的表达。结果耐药细胞多药耐药相关蛋白7表达升高;紫杉醇和吉西他滨胞内含量显著降低;参芪扶正注射液能显著升高化疗药对耐药细胞敏感性及胞内药物含量,并降低多药耐药相关蛋白7的表达。结论参芪扶正注射液可改善非小细胞肺癌(NSCLC)对紫杉醇及吉西他滨的耐药性。

Objective To investigate the effect and mechanism of Shenqi Fuzheng Injections on the resistance of lung cancer cells to paclitaxel and gemcitabine.Methods Different resistance cell lines were established,cell survival rate,intracellular drug content and multidrug resistance-associated protein 7（MRP7）expression were detected.Results The expression of MRP7 in drug-resistant cells increased;the intracellular content of paclitaxel and gemcitabine decreased significantly;Shenqi Fuzheng Injections significantly increased the sensitivity and intracellular drug content of chemotherapy drugs and decreased the expression of MRP7.Conclusion Shenqi Fuzheng Injections can improve the resistance of nonsmall-cell lung cancer（NSCLC）to paclitaxel and gemcitabine.